Stablix
New York City, US · 36 employees on LinkedIn · 1 known investors
Stablix is a preclinical-stage biotechnology company developing small-molecule medicines based on targeted deubiquitination therapeutics (TDT), using heterobifunctional molecules that recruit deubiquitinases (DUBs) to target proteins to restore protein stability and normal function. It focuses on treatments for cancer, rare diseases, and immunological disorders.
Founders & leadership
HC
Henry ColecraftCo-Founder & Chair of SAB
SK
Scott KannerCo-Founder & Scientific Advisor
ES
Eddine SaiahCEO and President
Investors · 1
Frequently asked questions
- What does Stablix do?
- Stablix is a preclinical-stage biotechnology company developing small-molecule medicines based on targeted deubiquitination therapeutics (TDT), using heterobifunctional molecules that recruit deubiquitinases (DUBs) to target proteins to restore protein stability and normal function. It focuses on treatments for cancer, rare diseases, and immunological disorders.
- Who founded Stablix?
- Stablix was founded by Henry Colecraft, Scott Kanner.
- Who are Stablix's investors?
- Stablix's investors include New Enterprise Associates (NEA).
- Where is Stablix headquartered?
- Stablix is headquartered in New York City, US.